INTRODUCTION
============

*H. pylori* INFECTION INDUCES BOTH A STRONG INFLAMMATORY CD4^+^ T CELL AND CD4^+^ T~reg~ RESPONSE
-------------------------------------------------------------------------------------------------

*Helicobacter pylori* chronically infects the mucus gel layer of the human stomach. This pathogen is highly adapted to the gastric niche and the natural immune response does not clear infection ([@B5]). Most cases of *H. pylori* gastritis are sub-clinical, and the inflammation leads to symptomatic gastritis in only about 10% of infected persons, the implications of asymptomatic infections remain unknown ([@B52]). *H. pylori* pathogenicity is dependent on both host and bacterial factors and the mechanisms are complex and remain to be explained clearly ([@B5]).

*Helicobacter pylori* gastritis is characterized by strong infiltrates of CD4^+^ T cells, Neutrophils and B cells ([@B6]; [@B56]) in the gastric mucosa. When one considers the high numbers of persons chronically infected with *H. pylori* worldwide, and that a relatively low proportion of these develop symptoms, it might be seen as circumstantial evidence that this inflammation is under tight regulatory control. Studies in biopsies from infected patients and experimental animals have supported the importance of suppressor or regulatory T cells (T~reg~) (CD4^+^/CD25^+^/FoxP3^+^) in *H. pylori* pathogenesis. Indeed relatively high numbers of *H. pylori*-specific T~reg~ are present in the stomach of asymptomatic *H. pylori*-infected patients ([@B35]; [@B16]) and that these suppressed memory T cell function *in vitro*. Similarly, studies in experimentally infected mice showed that T~reg~, suppressed proliferation of CD4^+^ T cells, and that this probably contributes to the persistence of the pathogen ([@B49]; [@B48]). In addition, these CD4^+^ T~reg~ have been shown to be specific for *H. pylori* antigens in humans ([@B6]) and mice ([@B50]). Further, [@B9] reported antigen-specific functional T~reg~ in the mucosa of patients with gastric tumors, it is noteworthy that greater numbers of T~reg~ were detected in tumors as opposed to non-tumor tissue. In this circumstance, T~reg~ may suppress natural protective anti-tumor mechanisms.

It is likely therefore that in most infected persons, *H. pylori* gastritis is tightly controlled by a complex balance of pro-inflammatory and suppressive T cells, and only when this balance is shifted by other factors do overtly pathogenic mechanisms move into action. The impact of these mechanisms is evident in the prevalence and clinical significance of gastric and duodenal ulcer disease, and gastric cancer. Understanding the factors influencing T~reg~ function in the stomach will be one of the keys to progress in therapy and vaccination against *H. pylori*.

GASTRIC T~reg~ AS AN OBSTACLE TO VACCINATION
============================================

The reports of successful immunization in animal models lead to early enthusiasm for a vaccine, and a variety of strategies, both oral and parenteral have been shown to be effective at reducing, but in general not completely clearing colonization (e.g., [@B2]; [@B42]). While there are some reports of sterilizing protection in mice ([@B26]; [@B15]; [@B44]) and in the gerbil model ([@B23]), the overwhelming majority of reports report 1--3 logs reduction in colonization, but not clearance (reviewed in [@B67]). Data from animal studies have showed that vaccine-induced protection is accompanied by increases in gastritis in vaccinated mice ([@B13]; [@B57]; [@B15]), prompting the general belief that strong inflammation is responsible for protection.

Early vaccine trials in human volunteers were disappointing with regard to efficacy, but showed that oral vaccination with recombinant antigens was at least feasible ([@B30]; [@B29]). Limited immunogenicity and a relatively high incidence of adverse effects were noted. Recent vaccine trials have reported good immunogenicity, e.g., a mixed antigen vaccine administered parenterally was immunogenic in *H. pylori* negative volunteers ([@B36]). However to date there have been only three trials in infected persons: two trials in *H. pylori*-positive volunteers ([@B30]; [@B29]) and one in prophylactically immunized and experimentally challenged volunteers ([@B1]). Although the vaccines were reported as safe, significant, if minor adverse effects were noted in all studies, and only very limited evidence of protective effects was obtained.

The impetus for vaccine development was lost because of the generally discouraging results discussed above. Progress in our understanding of the regulation of gastric inflammation, and pre clinical testing of new antigen combinations and adjuvant formulations are now a major focus. Questions have also been raised as to whether vaccination is even feasible, and indeed the obstacles are seemingly great. Given that the local gastric inflammatory response in natural infection is apparently so tightly regulated, a successful therapeutic vaccination strategy would need to overcome this regulation, without tipping the balance toward activating severe gastritis. T~reg~ may not be a hindrance to prophylactic vaccination, as they might not be expected to appear until several weeks/months after infection. Both prophylactic and therapeutic vaccination must also direct a protective response via the epithelium to clear an essentially extra cellular, motile, luminal pathogen.

Interest in an *H. pylori* vaccine has been rekindled with reports of increasing antibiotic resistance (particularly to metronidazole and clarithromycin; [@B20]). Vaccination experiments in knock-out mouse strains showed that in the absence of functional CD4^+^ T cells, vaccination was not protective ([@B10]; [@B46]). In addition, adoptive transfer of T cells (CD4^+^) from vaccinated mice conferred protection in *H. pylori*-challenged recipients ([@B37]; [@B34]). Although this model is not entirely straightforward and we have been able to reproduce these results in C57BL/6 mice in independent experiments in one laboratory but not after moving to another (Walduck and Becher, unpublished observations). The data from CD4-deficient mice are most compelling and clearly these cells are instrumental in mediating protection. On the other hand, T cell driven immune responses are also implied in induction of gastric neoplasia ([@B9]; [@B54]). Indeed [@B41] have shown evidence that the protective and pathogenic effects of T cells may be inseparable.

Others have suggested that there may be phenotypically different sub-populations of CD4^+^ cells that have protective effects ([@B4]; [@B63]). Evidence to support this will be discussed here.

With the importance of T~reg~ in *H. pylori* gastritis in mind, and the potential obstacles for vaccination, there is regrettably almost no information from the published human vaccine trials to date on the impact of vaccination on T~reg~. That T~reg~ may not interfere with prophylactic vaccination was supported by the report of [@B1], where FoxP3 positive cells were only detected in the mucosa in *H. pylori*-challenged volunteers after 3 months. There was however no significant effect of vaccination, at least up to 3 months when the study ended ([@B1], supplementary information).

Studies in animal models show significant populations of T~reg~ in *H. pylori*-infected mice ([@B50]), including in the stomach ([@B3]). Other studies showed that depletion of T~reg~ led to worsened gastritis ([@B24]). Depleting T~reg~ would be expected to improve vaccine efficacy by permitting increased pro-inflammatory responses, and this was reported by [@B66] who employed antigen pulsed DCs for vaccination. There are no other published reports of this phenomenon. There remain no published data from vaccination studies employing the mouse strain developed by Rudensky and colleagues ([@B25]) where depletion of T~reg~ can be selectively induced by injection of diphtheria toxin. This model offers the best possibility to determine the role for T~reg~ *in vivo*.

It should, however, be noted that alongside the reports of exacerbated gastritis in vaccinated mice, there are also numerous reports of effective vaccination (1--3 logs reductions in colonization) in other strains of mice, e.g., BALB/c, where gastritis minimal, or undetected by traditional methods ([@B17]; [@B34]; [@B43]). This implies that gastritis *per se* is not they key requirement for a protective response and that is the first suggestion that small protective sub-populations are present.

We have investigated CD4^+^ and CD4^+^ T~reg~ function in vaccinated C57BL/6 mice and compared gastric infiltrates to those in the circulation, spleen and lymph nodes. We found not only increased numbers of CD4 in the stomachs of vaccinated mice (as has been reported by others) but also decreased proportions of the T~reg~ sub-population of CD4^+^ cells in the stomach. These data imply that vaccination reduced suppression of CD4^+^ T cell numbers and function, and predicts that these cells will have a higher proliferative capacity. This was indeed observed in *in vitro* studies ([@B3]).

The lack of requirement of antibody ([@B10]) and many inflammatory cytokines including IFNγ, for vaccine mediated reductions in colonization, was unexpected in light of the strong Th1 response induced both infection and vaccination (reviewed in [@B2]). Gene expression studies were an alternative attempt to identify new pathways and mechanisms involved in protection ([@B39],[@B40]; [@B51]; [@B63]).

One of the novel signature genes identified in these studies was adipokines -- a family of genes associated with fat cells ([@B39]; [@B63]). *Adipokines* are defined as cytokines secreted by adipose tissue, many of which have endocrine activity. This group includes leptin, chemerin, resistin which have pro-inflammatory activity, and adiponectin which has anti-inflammatory activity ([@B31]; [@B18]; [@B65]).

A ROLE FOR LEPTIN IN REGULATING INFLAMMATION
============================================

Leptin (Ob -- the obese gene) is an adipocytokine that links nutrition with immunity. Adipokines are produced by mature adipocytes and other cell types (e.g., T cells, T~reg~, epithelial cells; [@B55]). Leptin (also known as Ob, the obese gene) is the best-studied adipokine to date, and acts as a hormone that regulates the perception of hunger, and therefore food and energy intake ([@B11]). Leptin has since also been implied in cytoprotection ([@B28]), bone mass control ([@B8]), and immune functions ([@B33]; [@B12]), including the effect of nutritional status on immune dysfunction ([@B45]).

The leptin receptor is a single transmembrane protein that is similar in structure to the gp130 family of receptors. Binding of the 16-kDa leptin protein triggers the receptor to form homodimers and induces signaling principally via the JAK/STAT pathway ([@B31]; **Figure [1](#F1){ref-type="fig"}**).

![**Structure of leptin receptor isoforms.** Ob-Rb contains the longest intracellular domain, which is crucial for leptin signaling. Ob-Ra, Ob-Rc, and Ob-Rd contain only short cytoplasmic domains. Ob-Re is truncated at position 830. Box 1 is a JAK docking site, boxes 2 and 3 are STAT docking sites. A point mutation at position 894 in the long form of ObR in the *db/db* mouse renders it incapable of signaling. The *db/db* mouse is a well-characterized model for type I diabetes and these congenic mice have a single nucleotide mutation that result in splicing of a non-functional version of the major signaling isoform Ob-Rb.](fimmu-03-00316-g001){#F1}

Ob-Re binds leptin but has no intracellular domain and although there is a report that it can initiate signaling, is thought to act chiefly as a method of storing leptin and as such prevents signaling and transport of leptin ([@B61]). Leptin receptor-signaling deficient mice are obese, and diabetic and display a marked increase in the number and suppressive function of T~reg~ cells ([@B60]). Leptin can also directly regulate T~reg~ function by acting as a strong has a strong inhibitor of proliferation ([@B7]).

Leptin also acts as a chemo-attractant for neutrophils and macrophages ([@B38]; [@B21]), these cells are also present in high proportions in vaccinated stomachs ([@B3]). Both macrophages and neutrophils are thought to migrate in response to local leptin gradients in tissues. Interestingly, *in vitro* stimulation via the leptin receptor induced migration, but not activation of neutrophils and rendered them unresponsive to "classical chemotaxins" such as IL-8 ([@B38]). Conversely, leptin stimulation induced migration and activation (caused Ca^2+^ influx), but did not interfere with the ability of a macrophage cell line to respond to MCP-1 ([@B21]).

LEPTIN RECEPTOR SIGNALING IS REQUIRED FOR VACCINE-INDUCED PROTECTION
====================================================================

As part of the follow-up from gene expression studies, we tested prophylactic vaccination in leptin receptor signaling deficient C57BLKS Cg Lepr*db/db* mice, and found that they were not protected by prophylactic vaccination ([@B64]). This was in spite of developing (mild) gastritis and *H. pylori*-specific antibody. While the latter does not necessarily suggest a protective response, it does indicate that the *db/db* mouse is immunocompetent. We hypothesized that leptin signaling was required, not for mounting an *H. pylori*-specific response, but rather for transmitting the protective " message" from the mucosa to the gastric epithelium.

Taken together with the evidence from the literature on the influence of leptin signaling on T~reg~, macrophages, and neutrophils, it seems feasible that leptin signaling may also provide a link between CD4^+^ function and protection in wild-type mice.

Based on the literature, and results of our own experimental data discussed below, we proposed that leptin plays a key role in signaling between protective T cells and gastric epithelium.

Hypothesis:

-   That strong gastritis is not required for a protective immune response in vaccination -- a small sub-population with a "protective" phenotype is sufficient.

-   That leptin signaling regulates CD4 cell function by interfering with the function of T~reg~ and inflammatory cells in the stomach.

The above hypotheses lead to the following predictions:

Successful vaccination will be observed in mouse strains/models where gastritis is mild/undetectable.

BALB/c mice develop weak, or delayed gastritis after *H. pylori* infection ([@B32]; [@B44]). After vaccination, BALB/c mice develop increased (although mild) gastritis and are protected to similar level as strains that develop strong gastritis such as C57BL/6 ([@B17]; [@B27]; [@B44]; [@B63]; [@B58]). The reduced gastritis observed in BALB/c mice might be expected to be due to the Th2 bias and increased proportion of T~reg~ found in this strain ([@B53]), however, [@B24] reported that depletion of T~reg~ using anti-CD25 antibody did not affect the intensity of gastritis, but the cytokine secretion pattern. The use of anti-CD25 antibodies could also have depleted other activated T cell populations and so the approach using specific *in vivo* depletion of T~reg~ discussed above will be required to clarify this question.

It is interesting to note that while CBA mice, which also develop only mild gastritis, were protected by prophylactic vaccination, therapeutic vaccination was ineffective ([@B59]). It would appear that additional genetic factors have a role to play in gastric inflammation.

If a small sub-population is responsible for protection, then a distinct phenotype of the protective will be recognizable, and small numbers will be required for protection.

The microarray studies that display a specific gene expression signature in protected mouse stomachs are indirectly suggestive of this protective phenotype ([@B40]; [@B51]; [@B63]). Further, analysis of gene expression patterns in biopsies from vaccinated human volunteers also suggested a specific expression pattern and "T cell footprint" ([@B1]).

Analysis of gene expression patterns in lymphocyte sub-populations isolated from gastric tissue of vaccinated and control mice will provide more specific information on the "protective program" induced in these cells.

Adoptive transfer studies where splenocytes or CD4^+^ cells from vaccinated mice were transferred to recipients provided confirmation for the importance of these cells for protection, relatively small numbers of cells are required to achieve this effect (in the order of 5 × 10^6^). These adoptively transferred cells do migrate to the gastric mucosa and are detectable in small numbers ([@B2]; Becher and Walduck, unpublished observations).

That vaccination will be ineffective in the absence of leptin

As discussed above, we reported the requirement for functional LepR signaling for protection in 2008 ([@B64]). The result was observed using two different prophylactic vaccination strategies. We have since also shown this in *db/db* mice backcrossed onto a C57BL/6 background (Becher et al., in preparation).

*If our previous observations hold, then leptin will impact CD4*^+^ T cells and T~reg~ proliferation and function.

The first suggestion for this comes from the analysis of gene expression patterns in the stomachs of vaccinated and non-protected *db/db* mice. For the most part, we observed the same genes were expressed in protected wild-type as obese mice, but interestingly, genes were more strongly up- or downregulated in obese *db/db* mice ([@B64]). This is suggestive of a lack of appropriate regulation or control of the inflammatory response in the absence of leptin signaling. Our observation is also in keeping with the reported role for LepR signaling in T~reg~ function. [@B7] proposed that T~reg~ control their own function in an autocrine fashion, by expressing both leptin and leptin receptor.

Based on the results of our previous descriptive studies on local gastric responses ([@B3]), we predicted that the role for leptin would be in a local gastric signaling network. Consistent with this proposal, we have detected both gastric epithelial cells and infiltrating lymphocytes express leptin receptor in *H. pylori*-infected mice (**Figure [2](#F2){ref-type="fig"}**).

![**Both leptin and leptin receptor are expressed locally in the gastric mucosa.** Immunohistochemistry using specific antibodies, detected with a Cy2 labeled secondary antibody. Both leptin **(A)** and lepR **(B)** are expressed in the gastric mucosa of vaccinated mice at day 21 post-challenge with *H. pylori* SS1. Mice were vaccinated with recombinant *S. typhimurium* expressing *H. pylori* urease as previously described ([@B3]). Original magnification ×20.](fimmu-03-00316-g002){#F2}

As a result of studies in models of both autoimmune and infection, leptin is now accepted to play an important role in regulating the Th1/Th2/T~reg~ balance ([@B47]), and in this manner to regulate disease. A number of recent publications point to the importance of leptin in T~reg~-associated disease which may well be applicable to the *H. pylori* system. T~reg~ play an important role in the complex inflammatory response in atherosclerosis ([@B19]). [@B22] reported that dysfunctional endothelial cells from idiopathic pulmonary arterial hypertension (IPAH) patients produced increased levels of leptin, and a higher proportion of their T~reg~ expressed leptin receptor. The authors hypothesize that leptin disregulates T~reg~ and contributes to disease ([@B22]). In addition, studies in mouse models of atherosclerosis revealed a critical role for leptin in the alteration of the regulatory immune response. Defective LepR signaling improved T~reg~, function and led to dramatic decreased in lesion size ([@B60]).

Given that leptin is ubiquitous in normal serum, *in vitro* studies on CD4^+^ T cell and T~reg~ function will not have addressed the situation of limiting leptin concentration, this point has also been raised by other authors ([@B7]). Available leptin concentrations in the tissue may well be lower than in standard tissue culture media. We are currently addressing this issue by examining the proliferative and suppressive ability of *H. pylori*-specific T~reg~ under leptin-limiting conditions.

Because commercially available antibodies detect all receptor isoforms, there is also little information on the expression of the various isoforms of on immune cell populations. We speculate that leptins' influence on T~reg~, CD4 and neutrophil function is orchestrated by expression of different receptor isoforms. Our preliminary analyses using an RT-PCR approach on sorted cell populations have shown that at least three different isoforms of LepR are expressed by CD4^+^ cells alone (**Figure [3](#F3){ref-type="fig"}**). We anticipate that further studies will reveal this repertoire may also be tissue-specific.

![**LeptinR isoforms Ob-Rb, Rc, and Re by murine CD4^+^ T cells.** Expression of leptinR isoforms by RT-PCR. CD4^+^ T cells were isolated and purified by negative selection from the MLN of *H. pylori*unvaccinated, infected female C57BL/6 mice. Equal amounts of MLN cDNA were analyzed for expression of Ob-Rb (295 bp), Ob-Rc (205 bp), and Ob-Re (257 bp, expression of Ob-Re is indicated with an arrow head). Positive control HPRT (399 bp), no RT control (control).](fimmu-03-00316-g003){#F3}

It remains to be demonstrated whether leptin receptor expression at the level of lymphocytes (CD4^+^ T cells or T~reg~), or indeed the gastric epithelium are most important in mediating the protective effects of vaccination. It is conceivable that leptin secreted by T cells may signal via LepR on gastric epithelial cells, and therefore mediate a protective response (**Figure [4](#F4){ref-type="fig"}**). Alternatively, LepR signaling on CD4^+^ T cells and/or T~reg~ may regulate inflammation and therefore the protective response. We are currently investigating these possibilities (Becher et al., in preparation). If these interactions are shown to play a significant role, it will be interesting to determine the extent to which they interact with the previously demonstrated role for IL-17 in protection and inflammation in *H. pylori* infection ([@B62]; [@B14]).

![**Possible role of leptin in inflammation and vaccine-induced protection.** In the vaccinated stomach, *H. pylori* challenge triggers CD4^+^ T cells, neutrophils, and macrophages to infiltrate the mucosa, proportions of T~reg~ are reduced. Two possible mechanisms are proposed for the manner in which leptin signaling is important for regulating this inflammation: **(A)** CD4^+^ T cells secrete leptin (black arrows), which acts as the message to stimulate epithelial cells to facilitate protective responses. **(B)** Alternatively, CD4^+^ T cells secrete leptin, which acts in an autocrine manner to stimulate their own proliferation, and suppress T~reg~ function. Leptin also affects macrophages and neutrophil function, depending on expression of specific LepR isoforms. This signaling induces secretion of other messages (gray arrow), which in turn stimulate epithelial cells to facilitate protective responses.](fimmu-03-00316-g004){#F4}

Our current studies are addressing a series of questions which we believe will provide a "road map" for testing the hypothesis:

-   Are the effects of leptin signaling mediated by direct action on epithelial cells, or immune (bone marrow-derived) cells the gastric mucosa?

-   Does *local* leptin production can affect T cell and T~reg~ function in the mucosa? Are the effects on these cells direct or indirect? Or is systemically produced leptin required?

-   And finally, and more speculatively is there a relationship between the effects of IL-17 and leptin in the stomach? It is possible that these mediators are part of the same local "program," or that their effects are specific and sequential.

In conclusion, we have provided evidence for the proposal that leptin has an important role in regulating T~reg~ and CD4^+^ T cell function in the gastric tissue. More detailed studies testing these hypotheses are underway and will ultimately clarify this. In the interim, we believe at least that this adipokine should be considered as an important player in the control of gastric inflammation.
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